News

An international collaboration has advanced therapies for co-occurring substance use disorders and PTSD and helped to inform prevention efforts globally.

Electronic health record-based screening for intimate partner violence prioritizes confidentiality.

Hollings was part of an international clinical trial that led to the FDA approval of a new drug to treat certain types of gliomas.

External evaluation of MUSC’s telestroke program confirms that stroke center certification and stroke coordinators improve stroke-care metrics.

MUSC’s pipeline programs build the skills of underrepresented students and prepare them for careers in health care and medical research.

Teams working to improve substance use screening in trauma centers and relieve symptoms of a connective tissue disease take home this year’s Blue Sky Awards.

The South Carolina Rare Disease Council hosted a symposium that gathered rare disease researchers and advocates to chart the path forward for improved care.

The annual PurpleStride walk raises money for pancreatic cancer research at Hollings Cancer Center.

Patrick Flume, M.D., was recently honored with the Cystic Fibrosis Foundation's 2024 Impact Award.

A new worldwide study finds the blood thinner apixaban to be successful in reducing stroke in patients with subclinical atrial fibrillation.